SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACO AMONG HIV-1 MEN AND WOMEN

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a pharmacokinetic (PK) evaluation of 78 HIV-infected individuals (39 men and 39 women) who are currently taking lopinavir/ritonavir (LPV/RTV) as part of their antiretroviral regimen. Plasma samples will be obtained prior to and up to 12 hours after the administration of the morning dose of LPV/RTV. This is the first large prospective study of sex differences in the PK of LPV/RTV in HIV-infected individuals. This data obtained will be used as a basis for proposing larger studies with additional drugs specifically looking at potential differences in efficacy and toxicity between the sexes, and to stimulate study into the mechanistic basis of this difference.